Unaudited Financial Results 31.12.2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
ANG Lifesciences reported weak Q3 FY26 results with standalone revenue from operations falling sharply by about 29.5% year-on-year to Rs 1,830.21 lakhs (vs Rs 2,597.05 lakhs in Q3 FY25). The company swung to a larger loss before tax of approximately Rs 497 lakhs in Q3 FY26 compared to a smaller loss of about Rs 62 lakhs in the year-ago quarter, driven by costs exceeding revenue. For the nine months ended December 2025, standalone revenue declined modestly to Rs 6,880.44 lakhs with a loss before tax of around Rs 662 lakhs. Consolidated nine-month revenue stood at Rs 7,194.10 lakhs with a loss of about Rs 970 lakhs. Statutory auditor Khurana Sharma & Co. issued an unmodified (clean) limited review opinion on both standalone and consolidated results. EPS for Q3 FY26 was Rs (7.86).
Sharp quarterly revenue contraction and widening losses signal continued operational stress, likely weighing negatively on near-term investor sentiment. Shareholders should monitor margin recovery, cost rationalisation and any turnaround measures in upcoming quarters.